A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 25 May 2017

At a glance

  • Drugs Blisibimod (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Registrational; Therapeutic Use
  • Acronyms CHABLIS-7.5
  • Sponsors Anthera Pharmaceuticals
  • Most Recent Events

    • 27 Feb 2017 Status changed from recruiting to discontinued, according to an Anthera Pharmaceuticals media release. The company has terminated the study based on the outcome of the CHABLIS-SC1 (profile 700202944) clinical study, and decided to discontinue the development of blisibimod for systemic lupus erythematosus (SLE).
    • 09 Aug 2016 Accoridng to Anthera media release, first patient has been enrolled in this study.
    • 09 Jun 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top